MicroRNA-150 and microRNA-155 in Multiple Sclerosis

March 5, 2020 updated by: Lamia Ahmed, Assiut University

MicroRNA-150 and microRNA-155 as Molecular Biomarkers in Multiple Sclerosis

A study To analyse the expression of circulating miR-150 and miR-155 in serum of MS patients, Evaluate the serum levels of oligoclonal bands, neurofilaments and chitinase-3-like-1 in serum of MS patients, and Investigate the correlation between the measured biomarkers and each other and their correlation with different MS phenotypes , disability status and the patients demographic data.

Study Overview

Status

Unknown

Conditions

Detailed Description

Multiple sclerosis (MS) is a chronic neurodegenerative autoimmune disease characterized by infiltration of immune cells into the central nervous system (CNS) with subsequent demyelination, axonal degeneration and neuronal death MS is the most common cause of non traumatic lifelong disability in young adults, affecting women almost three times as often as men

The incidence of MS is increasing worldwide, together with the socioeconomic impact of the disease There is no definite measure or laboratory marker for the diagnosis of MS yet In a patient presenting with an attack, the most important paraclinical test is magnetic resonance imaging (MRI) with intravenous (iv) contrast agent containing gadolinium. This can both present the nature of the lesions (inflammatory and demyelinating characteristics) for differential diagnosis, and the distribution of the lesions within the CNS (evidence of dissemination in time [DIT] and space [DIS] according to the latest McDonald Criteria (2017) Clinical and imaging findings that may be seen in MS, can also be mimicked by some infectious, neoplastic, genetic, metabolic, vascular and other idiopathic inflammatory demyelinating disorders (IIDD) Therefore, to identify MS-related attacks and determine the final diagnosis is vital for the correct treatment choice and longterm disability prevention.

The currently used biomarkers for diagnosing of MS include IgM and IgG antibodies , chemokines, glycoproteins and cell surface markers of inflammation . However, the disease course is very diverse and the heterogenesity in its phenotype not well correlated with biomarkers currently used thus, it is compulsory to identify new specific biomarkers that can help in distinguishing the different MS phenotypes , anticipate the progress of the disease and afford a correlate with the disability status

So, why are biomarkers for MS still arousing interest? Emerging biomarkers, such as circulating miRNAs, display several advantageous features in comparison with previous methods , The possibility to support the results of the clinical diagnosis distinguishing MS subtypes (PPMS, RRMS, etc.) and quantify MS severity , the fact that collecting blood miRNAs and measuring their expression is easy, poorly invasive, and cheap , the robustness of circulating miRNAs which are highly stable, and the accuracy using composite biomarkers rather than a single one.

MicroRNAs (miRNAs) are small non-coding RNA molecule (containing about 22 nucleotides) found in plants, animals and some viruses, that functions in RNA silencing and post-transcriptional regulation of gene expression.

One miRNA can regulate several targets and one target can be regulated by several miRNAs, so miRNAs have multiple biological functions including cell proliferation and differentiation, as well as immune function

The great stability of miRNAs in body fluids, as well as, the sensitive methods for their detection and quantification has led to circulating miRNAs being investigated as biomarkers for various human diseases New evidence has highlighted that miRNA production and trafficking can be dysregulated in both autoimmmune and neurological disorders.

miRNAs are also dysregulated in MS body fluids, including plasma, serum and cerebrospinal fluid.

So more understanding of altered miRNAs expression pattern has enormous potential to be used as diagnostic biomarkers for MS and for monitoring disease progression as well as developing novel therapeutic strategies.

One miRNA with a role in immune function is miR-150, numerous studies suggest that miR-150 regulates maturation and activation of lymphocytes A recent study confirmed that miR-150 controls B cell development by targeting transcription factor c-myb Subsequent studies showed that miR-150 is inversely associated with immunologic functions of activated B and T cells. miR-150 knockout (KO) mice have been shown to enhance T cell-dependent antibody responses and increased steady-state immunoglobulins

Despite considerable data on this molecule, its role in autoimmune disease in particular in multiple sclerosis (MS) is still unknown , miR-150 levels show promising biomarker potential in MS as it can aid in discriminating RRMS from controls Higher levels observed in patients with CIS who converted to MS compared to non converters suggest an involvement in MS progression . So miR-150 may be a novel biomarker of inflammatory active disease with the potential to be used for early diagnosis of MS Another microRNA involved in immune mechanisms is miR-155 which considered a central proinflammatory mediator of CNS It plays a critical role in hematopoietic cell development and tightly regulates innate and adaptive immune responses in response to infection. its dysregulation, more specifically its overexpression, is closely associated with various inflammatory disorders. Although many advances have been made understanding the role of miR-155 in immune cell function and regulation, there are many gaps in understanding its role in non-immune cells. Furthermore, the exact contribution of miR-155 in MS has not been directly explored to understand whether miR-155 is simply a marker for inflammation or whether it plays a predominant role in triggering MS.

Oligoclonal bands are bands of immunoglobulins that are seen when MS patient's blood serum and CSF are analyzed in parallel They are created by immunoglobulin G (IgG) and M (IgM) produced by plasma cells ,they found in nearly all patients with clinically definitive MS. However, OCB are not MS specific and can also occur in other inflammatory CNS diseases . If other diagnoses are excluded though, OCB support the diagnosis of MS. The detection of oligoclonal IgG bands in CSF is associated with a conversion from CIS to MS and can therefore be described as a biomarker for MS prognosis.

Neurofilaments (NF) are neuronal cytoskeletal proteins consisting of a light (NFL), an intermediate (NFM), and a heavy (NFH) chain . They determine the diameter of axons and are involved in axonal transport. If axonal or neuronal damage occurs, NF are released and can be detected in the CSF and blood.

Neurofilaments are emerging as promising new biomarkers for MS, their relative stability and abundance in CNS tissue make them ideal biomarker candidates to monitor ongoing axonal injury and neurodegeneration While these studies are promising, more studies are necessary to determine the sensitivity and specificity of these biomarkers. And a remaining concern regarding neurofilament testing in CSF is the need for repeated LP. So, whether blood levels of neurofilaments sufficiently correlate with disease activity and axonal loss remains to be determined.

Chitinase-3-like-1 Is chitin-binding protein homologous to chitinases, but lacking their capacity for chitin hydrolysis. In MS brain tissue, CHI3L1 (also known as YKL-40) is expressed in astrocytes in white matter plaques and in normal appearing white matter, and is also expressed in microglia in MS lesions. Elevated levels were found in optic neuritis, CIS and MS, So considered as prognostic biomarker for conversion from CIS or optic neuritis to definite MS. But, Its role as a biomarker for disease activity or disease progression is less clear. As its ability to discriminate between SPMS/PPMS and RRMS is not consistent .It also remains unclear whether serum levels of CHI3L1 can provide the same prognostic value as CSF levels

Study Type

Observational

Enrollment (Anticipated)

140

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 68 years (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

140 participants will be enrolled into a study to examine the microRNA and other mentioned biomarkers in their serum, Study population will consist of a total of :80 MS patients recruited among the attendants of out and in patients of neuropsychatric department, 40 with other neurological diseases , 20 healthy control

Description

Inclusion Criteria:

Patients diagnosed as MS (clinically and by imaging) according to revised 2017 McDonald Criteria .

Each patient will be subjected to complete medical history uptake including : Age, Sex, age at onset of the disease, phenotype of the disease and its duration, frequency of relapses and remissions , EDSS(The Expanded Disability Status Scale ) is a method of quantifying disability in multiple sclerosis) and MRI findings.

Exclusion Criteria:

  • Patients with non neurological autoimmune diseases, malignancy, cardiac and renal diseases that can affect level of miRNAs .

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Group 1 MS patients
patients with multiple sclerosis
Group 2 patients with other neurological disorders
patients with inflammatory or non inflammatory neurological diseases other than multiple sclerosis
Group 3 healthy control
No neurological or immunological disease

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
analyse the expression of circulating miR-150 and miR-155 in serum of MS patients
Time Frame: baseline
to measure the levels of miR-150 and miR-155 in different MS phenotypes
baseline
Evaluate the serum levels of oligoclonal bands, neurofilaments and chitinase-3-like-1 in serum of MS patients
Time Frame: baseline
measure the levels of OCB, NF-L and NF-H , and CHI3L1 in different MS phenotypes
baseline

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Investigate the correlation between the measured biomarkers and each other and their correlation with different MS phenotypes , disability status and the patients demographic data
Time Frame: baseline
investigate if the measured biomarkers can distinguish between MS phenotypes, and if they correlate with each other and with the disability status and the patients demographic data
baseline

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Assiut University

Investigators

  • Study Director: Sahar Eldeek, Ph.D., Assiut University
  • Study Director: Sally Mohamed, Assiut University
  • Principal Investigator: Lamia Ahmed, Assiut University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ANTICIPATED)

April 1, 2020

Primary Completion (ANTICIPATED)

April 1, 2021

Study Completion (ANTICIPATED)

October 1, 2021

Study Registration Dates

First Submitted

March 5, 2020

First Submitted That Met QC Criteria

March 5, 2020

First Posted (ACTUAL)

March 9, 2020

Study Record Updates

Last Update Posted (ACTUAL)

March 9, 2020

Last Update Submitted That Met QC Criteria

March 5, 2020

Last Verified

March 1, 2020

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • MicroRNAs in MS

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Multiple Sclerosis

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Slovenia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe